{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:32:10Z","timestamp":1782739930975,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ALK Positive, Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cllc.2025.05.009","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:31:05Z","timestamp":1749065465000},"page":"470-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry"],"prefix":"10.1016","volume":"26","author":[{"given":"Hayat","family":"Bazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Thuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Sravanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faten","family":"Abda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aula","family":"Alqased","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swara","family":"Chindhade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Snounu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Yaakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Culver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morhaf Al","family":"Achkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cllc.2025.05.009_bib0001","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/COC.0000000000000508","article-title":"Anaplastic lymphoma kinase (ALK)-positive tumors: clinical, radiographic and molecular profiles, and uncommon sites of metastases in patients with lung adenocarcinoma","volume":"42","author":"Gupta","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.05.009_bib0002","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11523-023-00973-7","article-title":"ALK inhibitor treatment patterns and outcomes in real-world patients with ALK-positive non-small-cell lung cancer: a retrospective cohort study","volume":"18","author":"Wang","year":"2023","journal-title":"Target Oncol"},{"issue":"10299","key":"10.1016\/j.cllc.2025.05.009_bib0003","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2025.05.009_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000524","article-title":"How I treat ALK-positive non-small cell lung cancer","volume":"4","author":"McCusker","year":"2019","journal-title":"ESMO Open"},{"issue":"18","key":"10.1016\/j.cllc.2025.05.009_bib0005","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non\u2013small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cllc.2025.05.009_bib0006","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jtho.2018.12.014","article-title":"Natural history and factors associated with overall survival in stage IV ALK-rearranged non\u2013small cell lung cancer","volume":"14","author":"Pacheco","year":"2019","journal-title":"J Thor Oncol"},{"key":"10.1016\/j.cllc.2025.05.009_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107919","article-title":"Real-world treatment sequencing and effectiveness of second-and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer","volume":"195","author":"Bauman","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.05.009_bib0008","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"Chia","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.cllc.2025.05.009_bib0009","first-page":"305","article-title":"Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non\u2013small cell lung cancer","volume":"28","author":"Ganti","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.cllc.2025.05.009_bib0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/CMAR.S393729","article-title":"Real-world treatment and outcomes of ALK-positive metastatic non\u2013Small cell lung cancer in a Southeast Asian country","volume":"15","author":"Poh","year":"2023","journal-title":"Cancer Manag Res"},{"issue":"4","key":"10.1016\/j.cllc.2025.05.009_bib0011","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3111\/13696998.2014.1003644","article-title":"Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden","volume":"18","author":"Gu\u00e9rin","year":"2015","journal-title":"J Med Econ"},{"issue":"12","key":"10.1016\/j.cllc.2025.05.009_bib0012","first-page":"3121","article-title":"Clinical characteristics and prognostic analysis of patients with ALK-positive lung cancer brain metastasis","volume":"146","author":"Zhang","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.05.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068832","article-title":"Symptoms and signs of lung cancer prior to diagnosis: case\u2013control study using electronic health records from ambulatory care within a large US-based tertiary care center","volume":"13","author":"Prado","year":"2023","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.cllc.2025.05.009_bib0014","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.radonc.2015.04.010","article-title":"Time to treatment as a quality metric in lung cancer: staging studies, time to treatment, and patient survival","volume":"115","author":"Gomez","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2025.05.009_bib0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2020.03.005","article-title":"Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer","volume":"143","author":"Sheinson","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.05.009_bib0016","series-title":"Cancer Registration: Principles and Methods","year":"1991"},{"issue":"6","key":"10.1016\/j.cllc.2025.05.009_bib0017","first-page":"1","article-title":"Time to diagnosis of lung cancer in relation to nodule size","volume":"219","author":"Suchsland","year":"2022","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.cllc.2025.05.009_bib0018","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/biomet\/63.3.581","article-title":"Inference and missing data","volume":"63","author":"Rubin","year":"1976","journal-title":"Biometrika"},{"issue":"14","key":"10.1016\/j.cllc.2025.05.009_bib0020","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non\u2013small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.05.009_bib0021","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.lungcan.2017.08.011","article-title":"Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review","volume":"112","author":"Jacobsen","year":"2017","journal-title":"Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:43:45Z","timestamp":1759351425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425001238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1525730425001238"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.05.009","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}